An Oncology Unscripted Episode
In this episode of Oncology Unscripted, hosts Mark Liu and Deirdre Saulet speak with James Riddle, MCSE, CIP, CPIA, CRQM, Senior Vice President of Global Review Services at Advarra, and Daniel Eisenman, PhD, RBP, SM(NRCM), CBSP, Executive Director of Biosafety Services at Advarra. Riddle and Dr. Eisenman explore the current landscape of cell and gene therapies in clinical trials and address bioethical and operational considerations as innovative treatments continue to emerge. They discuss the importance of informing patients fully of risk while preserving hope, why long-term follow-up is crucial for experimental therapy, and structural barriers that continue to impede patient access.
"I think investigators, particularly in the oncology space, have to have good experience. They have to have good training. They have to think not like a clinician sometimes, and more like 'I'm sitting down at the at the kitchen table and having a conversation with you as a fellow human being,' not with [their] white lab coat on" — James Riddle, MCSE, CIP, CPIA, CRQM
"From an ethical standpoint, I think it's extremely important, particularly in the research context, to make sure that folks do have access to participate in the clinical trials, because that gives us a more diverse population that are taking these experimental medications." — James Riddle, MCSE, CIP, CPIA, CRQM
"Currently, only about 20 to 30% of individuals that are eligible for CAR T-cell therapy actually end up receiving the therapy, because access is such a problem...We need to expedite the manufacturing process and increase accessibility." — Daniel Eisenman, PhD, RBP, SM(NRCM), CBSP
Guests:


James Riddle, MCSE, CIP, CPIA, CRQM
Senior Vice President of Global Review Services
Advarra


Daniel Eisenman, PhD, RBP, SM(NRCM), CBSP
Executive Director of Biosafety Services
Advarra
To submit a topic of discussion to the podcast, please email mark.liu@mountsinai.org and deirdre.saulet@hellojasper.com.
The views and opinions expressed herein are those of the author(s)/faculty member(s) and do not reflect the official policy or position of their employer(s) or the Association of Cancer Care Centers.
November 5, 2026
October 28, 2026
September 10, 2026